Sweden's Senzime Q1 sales dip on weak US markets, strong krona

Senzime AB (publ)

22/04/2026 07:08

Overview

Sweden medical device maker's Q1 net sales fell 1% yr/yr, currency-adjusted sales up 11%

Q1 EPS was negative, with gross margin before depreciation declining to 63.1% from 65.9%

US sales fell 5% due to delayed hospital contracts and stronger krona

Outlook

Senzime maintains target of reaching profitability by end of 2026

Company expects continued gross margin improvement and stable operating expenses in 2026

Senzime sees strong full-year growth for 2026 despite Q1 US market delays

Result Drivers

US CONTRACT DELAYS - Co said US sales were affected by delayed hospital contract decisions and a stronger krona, resulting in some orders shifting to Q2

COST CONTROL - Operating expenses fell about 5% due to strict cost control, according to CEO Philip Siberg

CURRENCY IMPACT - Stronger Swedish krona contributed to a temporary dip in reported growth, per CEO Philip Siberg

Company press release: ID:nMFN2Bl521

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
Miss
SEK 23.23 mln
SEK 34 mln (1 Analyst)
Q1 EPS
-SEK 0.14
Q1 Adjusted Gross Margin
63.10%
Q1 Operating Expenses
SEK 35.56 mln


Analyst Coverage

Wall Street's median 12-month price target for Senzime AB (publ) is SEK11.00, about 94.3% above its April 21 closing price of SEK5.66

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)